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Abstract  
The involvement of the diencephalic regions in neuromyelitis optica spectrum disorder (NMOSD) may 
lead to endocrinopathies. In this study we identified the following endocrinopathies in 60%(15/25) of 
young people with paediatric-onset AQP4-Ab NMOSD: morbid obesity (n=8), hyperinsulinaemia (n=5), 
hyperandrogenism (n=5), amenorrhoea (n=5), hyponatraemia (n=4), short stature (n=3) and central 
hypothyroidism (n=2) irrespective of hypothalamic lesions. Morbid obesity was seen in 88%(7/8) of 
children of Caribbean origin. As endocrinopathies, were prevalent in the majority of paediatric-onset 
AQP4-Ab NMOSD, endocrine surveillance and in particular early aggressive weight management is 
required for patients with AQP4-Ab NMOSD. 
.
 3 
Introduction 1 
The revised diagnostic criteria for neuromyelitis optica spectrum disorders (NMOSD) are considered to 2 
be appropriate for paediatric patients1. NMOSD-typical brain lesions may involve the diencephalic 3 
regions, including the hypothalamus, and the periependymal regions in the brainstem1, with consequent 4 
clinical symptoms. In particular, endocrinopathies and disorders of water balance, associated with CNS 5 
Aquaporin 4 (AQP4) autoimmunity, have been attributed to hypothalamic involvement.2  6 
 7 
An association between recurrent inflammation of the optic nerves and spinal cord with 8 
endocrinopathies was first described in 1997 in patients with the distinct clinical syndrome known as 9 
recurrent optic neuromyelitis (RONM); this was prior to the discovery of AQP4-Antibody (Ab). RONM 10 
was predominantly described in Afro-Caribbean and African-Brazilian women with recurrent CNS 11 
demyelination associated with endocrinopathies, such as central hypothyroidism, hyperphagia with 12 
obesity and diabetes mellitus3-5. The patients described with RONM would fulfil the current diagnostic 13 
criteria for neuromyelitis optica NMOSD1, even in the absence of AQP4-Ab. In view of the phenotypic 14 
overlap in patients with NMOSD and RONM, we aimed to investigate whether endocrinopathies are 15 
seen in paediatric onset AQP4-Ab positive NMOSD patients.  16 
 17 
Patients and methods  18 
Clinical, demographic and treatment data were collected from 25 consecutive paediatric-onset (under 19 
the age of 18 years) AQP4-Ab positive NMOSD patients, according to the recent diagnostic criteria1, 20 
seen in the nationally commissioned Oxford NMO service (NRES ref. 10/H0606/56). All patients had 21 
undergone brain and spinal cord imaging according to local MRI protocols.  Endocrinological tests were 22 
only carried out when clinically indicated. Morbid obesity was defined as BMI>40 and short stature was 23 
defined as height < 2SD below the mean height for age and sex. Hyperinsulinaemia was defined as 24 
HOMA-IR >1.5 or insulin peak >100 mU/l to oral glucose load. Amenorrhoea was defined as absence of 25 
periods by 16 years (primary) or absence of 3 consecutive periods in a woman with previously normal 26 
(monthly) cycles(secondary). Polycystic ovary syndrome was defined as An LH/FSH ratio of greater 27 
than 2.5:1. Central hypothyroidism was defined as low free T4/3 in the presence of a normal or low 28 
TSH.  Statistical analysis was performed using commercially available software GraphPad Prism 6 29 
[GraphPad Software Inc]). Non-parametric statistical tests (Mann-Whitney tests) were used for 30 
continuous distributions, and Fisher’s exact tests for nominal data. Parental consent was obtained for 31 
publication of relevant clinical information. 32 
 33 
Results  34 
The clinical and radiological features of all AQP4-Ab positive NMOSD patients are summarized in table 35 
1.  36 
 37 
 4 
A total of 15 patients (60%) had symptoms of endocrinopathies. These included: morbid obesity (n=8), 1 
hyperinsulinaemia (n=5), hyperandrogenism (n=5), secondary amenorrhoea (n=5), hyponatraemia 2 
(n=4), short stature (n=3) and central hypothyroidism (n=2).  3 
 4 
When comparing patients with endocrinopathies to those without, there was no difference in the 5 
patients’ demographics, clinical presentations at onset and relapse, or cumulative dose of steroids 6 
received (Table 1). Patients with endocrinopathies were more likely to have abnormal brain MRI 12/15 7 
than those without endocrinopathies during the course of their illness (12/15 vs 3/10 p=0.034), but there 8 
was no difference in hypothalamic involvement on imaging between patients with and those without 9 
endocrinopathies (4/15 vs 1/10, p=0.61). Morbid obesity was seen in 7/8 (87.5%) of children of 10 
Caribbean origin and only in one child (1/17, 5.9%) of non-Caribbean origin (p=0.002). Growth charts 11 
and neuroimaging of three female patients with morbid obesity are illustrated in Figure 1.  12 
 13 
Discussion  14 
In this cohort of paediatric onset AQP4-Ab NMOSD, we have identified endocrinopathies in 60% of the 15 
patients, contributing to significant morbidity with potential effect on the patients’ quality of life and long-16 
term health.  17 
 18 
It is possible that in some patients the endocrinopathies result from symptomatic hypothalamic lesions 19 
resulting in dysregulation of the homeostatic control of energy balance, which leads to metabolic 20 
alterations and obesity.6 In the original description of RNMO with endocrinopathies both enhancing and 21 
non-enhancing hypothalamic MRI lesions were observed in several patients. In addition inflammatory 22 
lesions were observed in hypothalamic area in one patient at pathological level3,4. Interestingly, no 23 
difference, in terms of evident of hypothalamic involvement, at the time of study, between patients with 24 
endocrinopathies and those without were observed in our cohort. This is in keeping with previous 25 
paediatric case reports of hypothalamic–pituitary axis dysfunction in children with NMOSD occurring 26 
with7 or without8 radiological evidence of hypothalamic inflammation. As not all patients were imaged 27 
with 3T MRI and it is possible that low field MRI could explain this discrepancy. More advance imaging 28 
techniques may detect microscopic tissue abnormalities suggestive of active inflammation or evidence 29 
of previous lesions in the hypothalamus 30 
 31 
Hyperinsulinaemia was only seen in patients with obesity and it is possibly a consequence of the 32 
obesity. Hyperandrogenism with polycystic ovary syndrome and secondary amenorrhoea were seen in 33 
5/25 (20%) of the patients; three with obesity and two with normal BMI. A previous study of paediatric 34 
NMOSD described 3 (out of 9) patients with irregular menstrual cycles before their initial attack, which 35 
became regular when patients were commenced on treatment9. In the same study catamenial 36 
exacerbation of disease occurred in one patient, and initiating oral contraceptives corresponded with 37 
 5 
decreased attacks. Hyponatraemia, secondary to syndrome of inappropriate antidiuretic hormone 1 
secretion (SIADH) was reported in 4/25 (16%) patients, all at presentation, which resolved with 2 
treatment, in keeping with recent reports of SIADH in 6/41 (15%) of adult patients with AQP4-Ab 3 
NMOSD10. 4 
 5 
Six of 15 (40%) patients with endocrinopathies in our cohort were of African-Caribbean origin. Although 6 
some of these features, in particularly the obesity, were initially attributed to the use of steroids, the 7 
patients continued to gain weight (>100kg addition in 2 patients over 2 and 3 years respectively) after 8 
steroids were stopped (Figure 1). It is possible that the exogenous corticosteroids may induce 9 
epigenetic changes in the glucocorticoid receptors resulting in chronic increases in hypothalamic 10 
corticosterone levels and consequent obesity and hyperphagia, as recently reported in an animal 11 
model11. Although obesity is common in British women of African-Caribbean origin, there is no 12 
straightforward relationship between obesity and ethnicity, with a complex interplay of factors that 13 
subsequently contribute to nutrition-related diseases. 14 
 15 
A major limitation of this study is the lack of standardised endocrinological assessment in the patients 16 
for hypothalamic-pituitary axis dysfunction throughout the disease course. Furthermore, it is likely that 17 
some of the features, such as the obesity, are multifactorial making it difficult to disentangle in this small 18 
cohort.  Nevertheless, the striking finding of endocrinopathies in 60% in children with AQP4-Ab 19 
NMOSD, with morbid obesity in 86% of affected children of Caribbean origin should argue for endocrine 20 
surveillance and mandate early aggressive weight management in all patients with AQP4-Ab NMOSD. 21 
 22 
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Table 1: Comparison of clinical and paraclinical features in AQP4-Ab positive patients with and 2 
without endocrinopathies. 3 
 Endocrinopathies 
(n=15) 
No endocrinopathies 
(n=10) 
P value 
Age of disease onset 
(median, IQR) 
12 (8-14) 11 (8-15.5) 0.80 
Female  14 (93%) 10 (100%) 1.0 
Ethnicity 
Caucasian  5 (33%) 6 (60%) 0.24 
Afro-Caribbean  6 (40%) 1 (10%) 0.18 
Asian  4 (27%) 2 (20%) 1.0 
Other  0 (0%) 1 (10%) 0.4 
Disease course 
Optic nerve 7 (47%) 7 (70%) 0.41 
Cerebrum 7 (47%) 1 (10%) 0.088 
Brainstem  13 (87%) 5 (50%) 0.075 
Spinal cord  10 (67%) 7 (70%) 1.0 
Magnetic resonance imaging 
Abnormal Brain  12 (80%) 3 (30%) 0.034 
Hypothalamic involvement  4 (27%) 1 (10%) 0.61 
 
Expanded Disability Status 
Scale (median, IQR) 
2 (1.5-3) 2.5 (1-4) 0.59 
 
Maintenance treatment 14 (93%) 8 (80%) 0.54 
Maintenance oral 
prednisolone (>3months)  
7 (47%, 1 obese 
patient) 
7 (70%) 0.41 
Rituximab 5 (33%) 0 (0%) 0.06 
Azathioprine/ Mycophenolate 
mofetil 
11 (73%) 7 (70%) 1.0 
 4 
 5 
 6 
 7 
 8 
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 7 
Figure 1: Growth charts of the three female patients with NMOSD and morbid obesity. 1 
Hypothalamic lesions on MRI were reported in patients 1 and 3 but not in patient 2. Patient 1 first 2 
presented with an area postrema syndrome at the age of 12 years. Her weight on presentation was 3 
63kg (BMI 21). She was referred to endocrinology service at age 12.5 years due to concerns about her 4 
weight (BMI 36.7  +3.5 SDS). She was not on steroids. She was noted to have striae, acanthosis 5 
nigricans and mild acne but no other Cushingoid features. She was also oligomenorrhoeic. Basal 6 
endocrine testing was normal. A subsequent oral glucose tolerance test performed at age 12.6 years 7 
showed a impaired fasting glucose (6.2 mmol/l), impaired glucose tolerance (9.0 mmol/l) and a peak 8 
insulin concentration that was above the upper limit of detection of >300 mU/l. She was subsequently 9 
started on metformin in escalating doses. At the age of 13.2 years, due to continued oligomenorrhoea, a 10 
pelvic ultrasound was performed which showed polycystic ovaries. However, despite dietary advice, at 11 
the age of 14 years her weight has increased to 162kg (BMI 55, > + 4SDS).  Patient 2 first presented 12 
with area postrema syndrome at the age of 10 years. Her weight on presentation was 43.5kg  (BMI 13 
21.9). She was seen by the endocrinology service at age 12.0 years. She was menarchal. She was 14 
noted to be obese (BMI 27.6, +2.7 SDS) with some hirsutism, and subsequently developed striae and 15 
acanthosis nigricans, and was noted to be Cushingoid. Baseline endocrine testing revealed central 16 
hypothyroidism (free T4 6.8 pmol/l (normal range 10.8-19.0), free T3 5.9 pmol/l (normal range 6.2-9.5), 17 
TSH 1.5 mU/l (normal <6.0)) and marked insulin resistance (fasting glucose 5.2 mmol/l, fasting insulin 18 
75.3 mU/l, HOMA-IR 17.3). Her endocrine status was otherwise normal. She was subsequently started 19 
on levothyroxine supplementation and metformin. Despite rapidly increasing doses of levothyroxine and 20 
metformin, her weight continued to escalate, a pelvic ultrasound at the age of 13.5 years revealed 21 
polycystic ovaries, although she was still experiencing regular periods. After prednisolone was stopped 22 
her BMI decreased to 44.4 from a peak of 49.8(+4.1 to +3.9 SDS). However, despite dietary advice and 23 
increasing her levothyroxine and metformin to maximum doses, she continued to gain weight. At the 24 
age of 15.5 years and a BMI of 46.9 (+4.0 SDS), she was referred for bariatric surgery. Patient 3 first 25 
presented with encephalopathy at the age of 10 years.  Neuroimaging revealed signal changes through 26 
amygdala, temporal lobes hypothalamus and dorsal medulla and an longitudinally extensive transverse 27 
myelitis At the time of admission her weight was 56kg (BMI 22). At the age of 12.7 years, patient 3’s 28 
escalating obesity (BMI 35.5, +3.4 SDS) led to an endocrinology review where she was found to be in 29 
late puberty (Tanner stage 4) but had not attained menarche. Baseline endocrine function was normal. 30 
Her weight continued to escalate despite continued efforts at dietary restriction and lifestyle changes, 31 
and at 13.1 years her BMI was 42.5 (+3.8 SDS). Examination revealed significant striae and 32 
Cushingoid features but spontaneous onset of menarche. Sequential trials of metformin and orlistat 33 
were instituted, but both caused significant side effects (abdominal pain and headaches) and were 34 
subsequently stopped. At the age of 13years, her prednisolone was weaned and stopped. In 35 
combination with dietary restriction, this led to a degree of weight loss and at last follow-up she had lost 36 
9.5 kg.37 
 8 
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